MRSA
The Unmet Need of MRSA in Osteomyelitis & Infective Endocarditis
Methicillin-resistant Staphylococcus Aureus (MRSA) has been a serious global threat since first discovered in 1961. A bacteria resistant to several antibiotics, it is globally prevalent with varying strains across all continents and manifesting in a wide range of infections including, osteomyelitis (OM), infective endocarditis (IE), pneumonia, and skin and soft tissue infections.
Of the MRSA infections, Osteomyelitis (infection of the bone), and Infective Endocarditis (infection of the heart), are the most difficult to treat and have the highest unmet need with a mortality rate ranging from 14%-25%.
OM and IE infection cases are estimated to be 600,000 to 900,000 per year with increasing prevalence. And although data is limited, it is suspected that a large number of cases in LICs go unreported.
Charles Noble | PhD, Analytical and Bioanalytical Chemist/Formulations Expert
“Avoidance of PICC lines for treating MRSA indications with the Akagera drug regimen would be transformational. ”
Our Science
(Akagera medicines has achieved preclinical proof of concept)
Technology
Liposomal Nanotherapeutics represent a well-validated platform of drug delivery systems which are utilized to alter the biodistribution of the encapsulated drug and the exposure profile for the drug, impacting both the efficacy and the toxicity (the therapeutic index) of the active drug.
mechanism of action
Additional Resources & News